Trump says he’s taking malaria drug to protect against virus

Trump says he’s taking malaria drug to protect against virus

WASHINGTON — President Donald Trump said Monday that he is taking a malaria drug to protect against the new coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.

Trump told reporters he has been taking the drug, hydroxychloroquine, and a zinc supplement daily “for about a week and a half now.” Trump spent weeks pushing the drug as a potential cure or prophylaxis for COVID-19 against the cautionary advice of many of his administration’s top medical professionals. The drug has the potential to cause significant side effects in some patients and has not been shown to combat the new coronavirus.

Trump said his doctor did not recommend the drug to him, but he requested it from the White House physician.

“I started taking it, because I think it’s good,” Trump said. “I’ve heard a lot of good stories.”

The Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings, due to sometimes fatal side effects. Regulators issued the alert for the drug, which can also be used to treat lupus and arthritis, after receiving reports of heart rhythm problems, including deaths, from poison control centres and other health providers.

Trump dismissed reports of side effects, saying, “All I can tell you is, so far I seem to be OK.”

At least two White House staffers tested positive for COVID-19 earlier this month, sparking concerns about the steps taken by the administration to protect the president and sending Vice-President Mike Pence and other officials into varying forms of self-isolation.

The White House has since mandated that those in the West Wing wear face coverings and has introduced daily testing for the virus for the president, vice-president and those they come in close contact with. Trump says he continues to test negative for the coronavirus.

Trump last underwent an “interim” checkup in a November visit to Walter Reed National Military Medical Center that was not noted on his public schedule. His last complete physical took place in February 2019.

Several prominent doctors said they worried that people would infer from Trump’s example that the drug works or is safe.

“There is no evidence that hydroxychloroquine is effective for the treatment or the prevention of COVID-19,” said Dr. Patrice Harris, president of the American Medical Association. “The results to date are not promising.”

People should not infer from Trump’s example “that it’s an approved approach or proven,” because it’s not, said Dr. David Aronoff, infectious diseases chief at Vanderbilt University Medical Center in Nashville.

Hydroxychloroquine can cause potentially serious heart rhythm problems even in healthy people, but “it’s hard to infer” that Trump’s artery plaque, revealed in tests from his 2018 physical, makes the drug especially dangerous for him, Aronoff said.

White House officials did not make the president’s physician, Navy Cdr. Dr. Sean Conley, available for comment, nor did they say whether any other administration officials were also taking the drug.

Trump said he took hydroxychloroquine with an “original dose” of the antibiotic azithromycin. The president has repeatedly pushed the use of the drug with or without the azithromycin, but no large, rigorous studies have found them safe or effective for preventing or treating COVID-19.

Two large observational studies, each involving around 1,400 patients in New York, recently found no benefit from hydroxychloroquine. Two new ones published Thursday in the medical journal BMJ reached the same conclusion.

One, by French researchers, gave 84 hospitalized patients the drug and 97 others the usual care. There were no differences in the odds of death, need for intensive care or developing severe illness.

The other study from China was a stricter test: 150 adults hospitalized with mild or moderate illness were randomly assigned to get hydroxychloroquine or usual care. The drug made no difference in rates of clearing the virus or time to relief of symptoms, and they brought more side effects.

In April, the National Institutes of Health launched a study testing hydroxychloroquine versus a placebo drug in 500 hospitalized COVID-19 patients. Last week, NIH announced another study to see if hydroxychloroquine plus azithromycin can prevent hospitalization or death in people with mild to moderate illness. About 2,000 U.S. adults with confirmed coronavirus infections and symptoms such as fever, cough or shortness of breath will get the drugs or placebo pills.

U.S. prescriptions for hydroxychloroquine surged roughly 80% in March to more than 830,000 compared with same period in the prior year, according to data tracking firm IQVIA. That jump in prescribing came before the federal government accepted nearly 30 million doses of the drug donated to the strategic national stockpile by foreign drugmakers. Since then, millions of those tablets have been shipped to U.S. hospitals nationwide for use treating patients with COVID-19.

—-

Marchione reported from Milwaukee. AP medical writer Matthew Perrone in Washington contributed to this report.

Zeke Miller, Marilynn Marchione And Darlene Superville, The Associated Press

Donald Trump

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

County of Paintearth releases summary of initial round of community engagement sessions

‘Various aspects of the existing Land-Use Bylaw and Municipal Development Plan were reviewed during the sessions’

County of Paintearth council hosts virtual delegation from RMA during June 2nd meeting

The RMA also usually hosts two conferences for municipalities in a given year

Alberta reports just seven new COVID-19 cases

‘Today’s numbers mark an occasion to be celebrated’

Still no confirmed active COVID-19 cases in Red Deer, central zone

There are 15 new confirmed cases were in Alberta, the province said Thursday

Town council moves to re-open community playgrounds

Highlights from the Town council meeting of May 25th

PODCAST: Black Lives Matter in central Alberta

Community organizers come on the show to discuss central Albertan anti-racist movement

‘It’s brewing’: Inmates, guards worry about violence after COVID-19 lockdown

‘Thirteen weeks in a cage the size of your (bathroom) has been pretty devastating’

Feds sign $105-million deal with Bombardier for two new Challenger jets

Department of National Defence announced the deal with Bombardier on Saturday

‘Alarmed:’ Health critic calls for more data on COVID-19 in trucking industry

Public Health Agency of Canada does not collect information on long-haul truckers

Montreal man believes rough arrest caught on video was racially motivated

Montreal man believes rough arrest caught on video was racially motivated

N.B. police shooting of Indigenous woman leads to questions on ‘wellness checks’

N.B. police shooting of Indigenous woman leads to questions on ‘wellness checks’

Minister says reckoning on police violence against Indigenous people needed

Minister says reckoning on police violence against Indigenous people needed

Nunavut to bring in civilian police review after arrest video: minister

Nunavut to bring in civilian police review after arrest video: minister

Most Read